Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Nicox News

    0,3415 € +3,64% +0,012 €
    09:27:54 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A143G8
    ISIN: FR0013018124
    US-Symbol: NICXF
    Typ: Aktie

    Nicox News

    24.04.24 - GlobeNewswire
    Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
    Press Release Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent April 24, 2024 – release at 07:30 ...
    22.04.24 - GlobeNewswire
    Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
    Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue 1 €3.9 million) for first quarter 2024 ...
    09.04.24 - GlobeNewswire
    Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
    Press Release Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting April 9, 2024 – release at 17:30 CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, ...
    22.03.24 - GlobeNewswire
    Nicox's Shareholder Letter
    Dear Shareholder,
    20.03.24 - GlobeNewswire
    Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
    Press Release
    13.03.24 - GlobeNewswire
    Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
    Press Release
    05.03.24 - GlobeNewswire
    Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
    Press Release
    28.02.24 - GlobeNewswire
    Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
    Press Release
    28.02.24 - GlobeNewswire
    Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
    Press Release
    08.02.24 - GlobeNewswire
    Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan
    Press Release Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan €3 million upfront payment and a total of a further potential €27.5 ...
    06.02.24 - GlobeNewswire
    Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
    Press Release Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 February 6, 2024 – release at ...
    31.01.24 - GlobeNewswire
    Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®
    Press Release Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA ® January 31, 2024 – release ...
    25.01.24 - GlobeNewswire
    Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
    Press Release Nicox Provides Fourth Quarter 2023 Financial and Business Highlights NCX 470 Phase 3 Denali clinical trial 75% randomized Net revenue €1.3 million for fourth ...
    18.12.23 - GlobeNewswire
    Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma
    Press Release Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma December 18, 2023 – release at 7:30 am CET Sophia Antipolis, ...
    14.12.23 - GlobeNewswire
    Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan
    Press Release Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan December ...
    20.10.23 - GlobeNewswire
    Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones
    Press Release Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones  Third quarter 2023 U.S. prescriptions for VYZULTA ® ...
    19.07.23 - GlobeNewswire
    Nicox Provides Second Quarter 2023 Financial and Business Highlights
    Press Release Nicox Provides Second Quarter 2023 Financial and Business Highlights Net revenue 1 of € 0.9 million for the second quarter of 2023 Cash position of € 19 .0 million ...
    10.07.23 - GlobeNewswire
    Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million
    Press Release Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million NCX 470 therapeutic profile positively received a m ong U.S. eye care ...
    03.07.23 - GlobeNewswire
    Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress
    Press Release Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma ...
    28.04.23 - GlobeNewswire
    Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China
    Press Release Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China Nicox’s p artner, Ocumension ...

    Newssuche

    Videos

    newspaper
    09:30 Uhr +45,53%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »